who underwent a more extensive pelvic lymph-node dissection (PLND) had a better CSS than those who underwent a more limited one. Our data support a possible role of PLND in cancer outcome. Although the extent of PLND may indirectly influence BCR because of the Will-Rogers phenomenon, the inclusion of both node-positive and node-negative patients may partially exclude this bias. Figure 1. 259 SIURO-PRIAS-ITA: FIRST YEAR <strong>ITALIAN</strong> EXPERIENCE IN <strong>THE</strong> PRIAS INTERNATIONAL COLLABORATIVE STUDY ON ACTIVE SURVEILLANCE Giario Conti1 , Tiziana Magnani2 , Roberto Salvioni3 , Sergio Villa4 , Michele Gallucci5 , Rocco Papalia5 , Giuseppe Martorana6 , Cosimo Bizzarri6 , Roberto Sanseverino7 , Giorgio Napodano7 , Pierpaolo Graziotti8 , Gianluigi Taverna8 , Roberto Peschechera8 , Andrea Turci9 , Giacomo Cicchetti9 , Enrico Bollito10 , Maurizio Colecchia11 , Rodolfo Montironi12 , Steno Sentinelli13 , Monique Roobol14 and Riccardo Valdagni2,4 1Dip. Chirurgia, Ospedale Sant’Anna, Como, Italy; 2Programma Prostata, 3SC Urologia, 4SC Radioterapia Oncologica 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; 5Div. Urologia, Istituto Regina Elena, Roma, Italy; 6Div. Urologia, Policlinico Sant’Orsola Malpighi, Bologna, Italy; 7Div. Urologia, Ospedale Umberto I, Nocera Inferiore, Italy; 8Div. Urologia, Istituto Clinico Humanitas, Rozzano, Italy; 9Div. Urologia, Ospedale M. Bufalini, Cesena, Italy; 10Servizio di Anatomia Patologica, Ospedale San Luigi Gonzaga, Orbassano, Italy; 11SC Anatomia Patologica, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; 12Servizio di Anatomia Patologica, Ospedali Riuniti, Torrette di Ancona, Italy; 1952 ANTICANCER RESEARCH 31: 1807-1956 (2011) 13 Servizio di Anatomia Patologica, Istituto Regina Elena, Roma, Italy; 14 Div. Urology, Erasmus Medical Center, Rotterdam, the Netherlands PRIAS is the acronym for Prostate cancer Research International: Active Surveillance, a large collaborative international study on observational strategy in low-risk prostate cancer patients, coordinated by the Erasmus University Medical Center in Rotterdam. Over two thousand patients have been enrolled since 2006. The Italian Society of Urological Oncology (SIUrO) joined the protocol in December 2009. Eligibility criteria were: PSA ≤10 ng/ml, Gleason score ≤6 or Gleason 3+4 in men >69 years old with
Abstracts of the <strong>21st</strong> Annual Meeting of the Italian Society of Uro-Oncology (SIUrO), 22-24 June, 2011, Naples, Italy Table I. Follow-up schedule. health-related quality of life. Exit criteria were: ≤3 years PSA-DT, progression in number of positive cores and/or Gleason score ≥7 at the follow-up biopsies (Gleason 3+4 is accepted in men >69 years old with